EyePoint Pharmaceuticals (EYPT) Stock Forecast & Price Target

Compare

932 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

EYPT Analyst Ratings

Strong Buy

7 Buy

0 Hold

0 Sell

Based on 7 analysts giving stock ratings to

EyePoint

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

EYPT Stock 12 Month Forecast

Average Price Target

$33.00

▲(134.88% Upside)

Based on 7 Wall Street analysts offering 12 month price targets for EyePoint Pharmaceuticals in the last 3 months. The average price target is $33.00 with a high forecast of $68.00 and a low forecast of $18.00. The average price target represents a 134.88% change from the last price of $14.05.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","21":"$21","37":"$37","53":"$53","69":"$69"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":68,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$68.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$33.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$18.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,21,37,53,69],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.71,14.193846153846154,18.677692307692308,23.161538461538463,27.645384615384614,32.129230769230766,36.61307692307692,41.096923076923076,45.58076923076923,50.06461538461538,54.54846153846153,59.03230769230769,63.51615384615384,{"y":68,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.71,11.501538461538463,13.293076923076924,15.084615384615386,16.876153846153848,18.667692307692306,20.45923076923077,22.25076923076923,24.042307692307695,25.833846153846153,27.625384615384615,29.416923076923077,31.20846153846154,{"y":33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.71,10.34769230769231,10.985384615384616,11.623076923076924,12.260769230769231,12.89846153846154,13.536153846153848,14.173846153846155,14.811538461538461,15.44923076923077,16.086923076923078,16.724615384615383,17.362307692307695,{"y":18,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":10.71,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.13,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.95,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.06,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.76,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.45,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.65,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.27,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.13,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.42,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.55,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.71,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$68.00

Average Price Target$33.00

Lowest Price Target$18.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Graig Suvannavejh

Mizuho Securities

$26→$28

Buy

99.29%

Upside

Reiterated

08/14/25

EyePoint Pharmaceuticals (EYPT) Receives a Buy from Mizuho Securities…and a high degree of confidence in the likelihood of Duravyu's P3 success, we reiterate our OP rating on EYPT.

Debanjana Chatterjee

JonesTrading

$41

Buy

191.81%

Upside

Reiterated

08/11/25

Analysts' Top Healthcare Picks: EyePoint Pharmaceuticals (EYPT), Axsome Therapeutics (AXSM)Wereiterate Buy & our $41 PT

Greg Harrison

Scotiabank

$18

Buy

28.11%

Upside

Reiterated

08/07/25

Scotiabank Sticks to Their Buy Rating for EyePoint Pharmaceuticals (EYPT)

Yatin Suneja

Guggenheim

$68

Buy

383.99%

Upside

Reiterated

08/06/25

With rapid execution in pivotal study enrollment, we reiterate our Buy rating and set a $68 price target.

Tyler Van Buren

TD Cowen

$20→$25

Buy

77.94%

Upside

Reiterated

08/06/25

EyePoint Pharmaceuticals: Promising Phase III Trials and Market Potential for Long-Acting TKI

Lisa Walter

RBC Capital

$28

Buy

99.29%

Upside

Reiterated

08/06/25

Analysts Offer Insights on Healthcare Companies: EyePoint Pharmaceuticals (NASDAQ: EYPT), NewAmsterdam Pharma Company (NASDAQ: NAMS) and Surgery Partners (NASDAQ: SGRY)

Yi Chen

H.C. Wainwright

$22→$23

Buy

63.70%

Upside

Reiterated

08/06/25

EyePoint Pharmaceuticals: Promising Phase 3 Trial Progress and Strategic Advancements Justify Buy Rating

Tessa Romero

J.P. Morgan

$26

Buy

85.05%

Upside

Reiterated

05/27/25

J.P. Morgan Keeps Their Buy Rating on EyePoint Pharmaceuticals (EYPT)

Jennifer Kim

Cantor Fitzgerald

―

Buy

―

Reiterated

02/05/25

EyePoint Pharmaceuticals (EYPT) decline "makes no sense", says Cantor FitzgeraldCantor Fitzgerald analyst Jennifer Kim reiterated an Overweight rating on EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) following VERONA data. Kim said the selloff in the stock "makes no sense.

Yigal Nochomovitz

Citi

$33

Buy

134.88%

Upside

Initiated

01/07/25

EyePoint Pharmaceuticals: Positioned for Growth with DURAVYU in the wAMD Market

Colleen M. Kusy

Robert W. Baird

$38→$33

Buy

134.88%

Upside

Reiterated

11/11/24

EyePoint price target lowered to $33 from $38 at BairdEyePoint price target lowered to $33 from $38 at Baird

Tim Chiang

Capital One Financial

$35

Buy

149.11%

Upside

Assigned

10/28/24

EyePoint Pharmaceuticals' Positive Clinical Data Boosts Buy Rating Amid Promising Eye Disease Therapies

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Graig Suvannavejh

Mizuho Securities

$26→$28

Buy

99.29%

Upside

Reiterated

08/14/25

EyePoint Pharmaceuticals (EYPT) Receives a Buy from Mizuho Securities…and a high degree of confidence in the likelihood of Duravyu's P3 success, we reiterate our OP rating on EYPT.

Debanjana Chatterjee

JonesTrading

$41

Buy

191.81%

Upside

Reiterated

08/11/25

Analysts' Top Healthcare Picks: EyePoint Pharmaceuticals (EYPT), Axsome Therapeutics (AXSM)Wereiterate Buy & our $41 PT

Greg Harrison

Scotiabank

$18

Buy

28.11%

Upside

Reiterated

08/07/25

Scotiabank Sticks to Their Buy Rating for EyePoint Pharmaceuticals (EYPT)

Yatin Suneja

Guggenheim

$68

Buy

383.99%

Upside

Reiterated

08/06/25

With rapid execution in pivotal study enrollment, we reiterate our Buy rating and set a $68 price target.

Tyler Van Buren

TD Cowen

$20→$25

Buy

77.94%

Upside

Reiterated

08/06/25

EyePoint Pharmaceuticals: Promising Phase III Trials and Market Potential for Long-Acting TKI

Lisa Walter

RBC Capital

$28

Buy

99.29%

Upside

Reiterated

08/06/25

Analysts Offer Insights on Healthcare Companies: EyePoint Pharmaceuticals (NASDAQ: EYPT), NewAmsterdam Pharma Company (NASDAQ: NAMS) and Surgery Partners (NASDAQ: SGRY)

Yi Chen

H.C. Wainwright

$22→$23

Buy

63.70%

Upside

Reiterated

08/06/25

EyePoint Pharmaceuticals: Promising Phase 3 Trial Progress and Strategic Advancements Justify Buy Rating

Tessa Romero

J.P. Morgan

$26

Buy

85.05%

Upside

Reiterated

05/27/25

J.P. Morgan Keeps Their Buy Rating on EyePoint Pharmaceuticals (EYPT)

Jennifer Kim

Cantor Fitzgerald

―

Buy

―

Reiterated

02/05/25

Yigal Nochomovitz

Citi

$33

Buy

134.88%

Upside

Initiated

01/07/25

EyePoint Pharmaceuticals: Positioned for Growth with DURAVYU in the wAMD Market

Colleen M. Kusy

Robert W. Baird

$38→$33

Buy

134.88%

Upside

Reiterated

11/11/24

EyePoint price target lowered to $33 from $38 at BairdEyePoint price target lowered to $33 from $38 at Baird

Tim Chiang

Capital One Financial

$35

Buy

149.11%

Upside

Assigned

10/28/24

EyePoint Pharmaceuticals' Positive Clinical Data Boosts Buy Rating Amid Promising Eye Disease Therapies

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering EyePoint Pharmaceuticals

1 Month

xxx

Success Rate

8/16 ratings generated profit

Average Return

+5.34%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +5.34% per trade.

3 Months

xxx

Success Rate

10/16 ratings generated profit

Average Return

+21.80%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 62.50% of your transactions generating a profit, with an average return of +21.80% per trade.

1 Year

Tyler Van BurenTD Cowen

Success Rate

8/10 ratings generated profit

Average Return

+28.57%

reiterated a buy rating 2 months ago

Copying Tyler Van Buren's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +28.57% per trade.

2 Years

xxx

Success Rate

9/10 ratings generated profit

Average Return

+46.68%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 90.00% of your transactions generating a profit, with an average return of +46.68% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

EYPT Analyst Recommendation Trends

Rating

Mar 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, EYPT has received 12 Buy Ratings, 11 Hold Ratings, and 0 Sell Ratings. EYPT average Analyst price target in the past 3 months is 33.00.

Each month's total comprises the sum of three months' worth of ratings.

EYPT Financial Forecast

EYPT Earnings Forecast

Next quarter’s earnings estimate for EYPT is -$0.77 with a range of -$0.94 to -$0.67. The previous quarter’s EPS was -$0.85. EYPT beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year EYPT has Outperformed its overall industry.

EYPT Sales Forecast

Next quarter’s sales forecast for EYPT is $3.46M with a range of $0.00 to $11.71M. The previous quarter’s sales results were $5.33M. EYPT beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year EYPT has Outperformed its overall industry.

EYPT Stock Forecast FAQ

What is EYPT’s average 12-month price target, according to analysts?

Based on analyst ratings, EyePoint Pharmaceuticals Inc’s 12-month average price target is 33.00.

What is EYPT’s upside potential, based on the analysts’ average price target?

EyePoint Pharmaceuticals Inc has 134.88% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is EYPT a Buy, Sell or Hold?

EyePoint Pharmaceuticals Inc has a consensus rating of Strong Buy which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.

What is EyePoint Pharmaceuticals Inc’s price target?

The average price target for EyePoint Pharmaceuticals Inc is 33.00. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $68.00 ,the lowest forecast is $18.00. The average price target represents 134.88% Increase from the current price of $14.05.

What do analysts say about EyePoint Pharmaceuticals Inc?

EyePoint Pharmaceuticals Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.

How can I buy shares of EYPT?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

EyePoint Pharmaceuticals (EYPT) Stock Forecast & Price Target

EYPT Analyst Ratings

EYPT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering EyePoint Pharmaceuticals

EYPT Analyst Recommendation Trends

EYPT Financial Forecast

EYPT Earnings Forecast

EYPT Sales Forecast

EYPT Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts